PT  - JOURNAL ARTICLE
AU  - David Couper
AU  - Lisa M LaVange
AU  - MeiLan Han
AU  - R Graham Barr
AU  - Eugene Bleecker
AU  - Eric A Hoffman
AU  - Richard Kanner
AU  - Eric Kleerup
AU  - Fernando J Martinez
AU  - Prescott G Woodruff
AU  - Stephen Rennard
AU  - for the SPIROMICS Research Group
TI  - Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)
AID  - 10.1136/thoraxjnl-2013-203897
DP  - 2014 May 01
TA  - Thorax
PG  - 492--495
VI  - 69
IP  - 5
4099  - http://thorax.bmj.com/content/69/5/492.short
4100  - http://thorax.bmj.com/content/69/5/492.full
SO  - Thorax2014 May 01; 69
AB  - Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.